A groundbreaking study reveals that insulin resistance, measured by the triglyceride-glucose (TyG) index, can be a crucial indicator of rapid cognitive decline in Alzheimer's patients. Those with higher TyG levels face a fourfold increase in deterioration rates, prompting new intervention strategies.
Research reveals that over 15 million people in the US, UK, Germany, and France are unaware they have metabolic dysfunction-associated steatotic liver disease, a condition linked to severe health risks. Experts call for increased screenings and diagnosis rates.
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
